Our performance and results
LEO Pharma’s annual reporting covers our financial reporting and sustainability reporting for the financial year from January 1 to December 31.
Read our 2022 Annual ReportOur press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request.. For updated information about clinical trials, please visit https://clinicaltrials.gov/ https://clinicaltrials.gov/.
Featured stories
- 14/03/23 LEO Pharma adds internationally recognized dermatologist to Global Leadership Team
- 10/03/23 LEO Pharma and ICON enter a Strategic Partnership to propel clinical trial execution within medical dermatology
- 09/03/23 LEO Pharma announces annual results 2022
- 12/01/23 Delivering a financial turnaround of LEO Pharma
- 31/08/22 LEO Pharma appoints Paul Navarre new member of its Board of Directors
- 18/08/22 LEO Pharma appoints new Chief Financial Officer and Executive Vice President
- 03/08/22 LEO Pharma appoints new Executive Vice President of Global Product Supply
- 28/06/22 LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors
- 02/06/22 LEO Pharma strengthens its commercial organization
- 21/04/22 LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative
- 17/03/22 LEO Pharma announces annual results 2021
- 17/02/22 LEO Pharma A/S appoints Brian Hilberdink new President of LEO Pharma Inc. United States
- 31/01/22 LEO Pharma appoints Christophe Bourdon as new CEO
- 19/01/22 LEO Pharma introduces new operating model to increase competitiveness and support future growth
- 05/01/22 LEO Pharma convene dermatology experts in global initiative on skin health
- 30/11/21 Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
- 15/11/21 LEO Pharma successfully refinances loan facility
- 29/09/21 LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
- 06/07/21 LEO Pharma and X-Chem Enter Into Discovery Research Agreement
- 22/03/21 LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
- 15/12/20 LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development
- 27/10/20 LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
- 22/09/20 LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
- 30/08/20 LEO Pharma sells portfolio of four products to Cheplapharm
- 19/08/20 LEO Pharma unveils ambitious 2030 strategy positioning itself for long-term growth driven by innovation
- 18/08/20 LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications
- 29/06/20 LEO Pharma strengthens global leadership team
- 12/03/20 Updates regarding COVID-19
- 20/11/19 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
- 18/11/19 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
- 13/11/19 Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
- 06/11/19 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
- 29/10/19 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
- 23/10/19 World Psoriasis Day 2019: LEO Pharma launches new campaign to reduce the stigma surrounding psoriasis
- 30/06/19 LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- 02/06/19 LEO Pharma appoints Catherine Mazzacco as new CEO
- 09/05/19 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
- 10/04/19 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
- 08/04/19 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
- 18/03/19 LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
MEDIA ENQUIRIES
